Takeda Pharmaceutical Company Limited (NYSE:TAK – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $12.77 and last traded at $12.80, with a volume of 130982 shares changing hands. The stock had previously closed at $13.17.
Takeda Pharmaceutical Stock Performance
The company has a market cap of $40.10 billion, a P/E ratio of 23.04, a price-to-earnings-growth ratio of 3.18 and a beta of 0.55. The company’s fifty day moving average is $13.23 and its 200 day moving average is $13.95. The company has a current ratio of 1.11, a quick ratio of 0.58 and a debt-to-equity ratio of 0.62.
Institutional Trading of Takeda Pharmaceutical
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. New York State Common Retirement Fund purchased a new position in Takeda Pharmaceutical during the 3rd quarter valued at about $145,000. Pathstone Family Office LLC purchased a new position in shares of Takeda Pharmaceutical during the third quarter valued at approximately $203,000. HighTower Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 17.4% during the third quarter. HighTower Advisors LLC now owns 83,720 shares of the company’s stock valued at $1,299,000 after acquiring an additional 12,423 shares in the last quarter. Citigroup Inc. lifted its stake in Takeda Pharmaceutical by 5.6% in the third quarter. Citigroup Inc. now owns 57,941 shares of the company’s stock worth $896,000 after acquiring an additional 3,089 shares during the period. Finally, Envestnet Portfolio Solutions Inc. bought a new stake in Takeda Pharmaceutical in the third quarter valued at $346,000. Institutional investors own 9.17% of the company’s stock.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Articles
- Five stocks we like better than Takeda Pharmaceutical
- The Most Important Warren Buffett Stock for Investors: His Own
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- Insider Trades May Not Tell You What You Think
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
